Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 17/20 | 1.00 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264626 | 1.00 | HCRTR2 (1.00) | HCRTR2HCRTR1MEN1KMT2AKDM4E | |
| SCHEMBL30417508 | 1.00 | HCRTR2 (1.00) | HCRTR2HCRTR1MEN1KMT2AKDM4E | |
| SCHEMBL12978652 | 1.00 | HCRTR2 (1.00) | HCRTR2HCRTR1MEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL15544842 | 0.99 | HCRTR2 (0.98) | HCRTR2HCRTR1MEN1KMT2AKDM4E | |
| SCHEMBL6333557 | 0.90 | HCRTR2 (1.00) | HCRTR2HCRTR1KMT2AKDM4EALDH1A1 | |
| SCHEMBL6328598 | 0.84 | HCRTR2 (0.81) | HCRTR2HCRTR1 | |
| SCHEMBL6978577 | 0.82 | HCRTR2 (0.72) | HCRTR2HCRTR1 | |
| SCHEMBL6327967 | 0.82 | HCRTR2 (1.00) | HCRTR2HCRTR1MEN1KMT2AKDM4E | |
| SCHEMBL6333854 | 0.82 | HCRTR2 (0.71) | HCRTR2HCRTR1KDM4EALDH1A1TSHR | |
| SCHEMBL6331702 | 0.82 | HCRTR2 (0.71) | HCRTR2HCRTR1KDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838465-B2 | N-acyltetrahydroisoquinoline derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-04 | — | — | US | disclosed |
| US-20040044031-A1 | N-acyltetrahydroisoquinoline derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-1288202-A1 | N-ACYLTETRAHYDROISOQUINOLINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044031-A1 | N-acyltetrahydroisoquinoline derivatives | HCRTR2, HCRTR1, OPRL1 | HCRTR2 1/4885HCRTR1 2/4885MEN1 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.